Sign in

    David Kwan • TD Cowen

    David Kwan's questions to WELL Health Technologies Corp (WHTCF) leadership

    David Kwan's questions to WELL Health Technologies Corp (WHTCF) leadership • Q1 2025

    Question

    David Kwan from TD Cowen inquired about the status of the OceanMD contract in British Columbia, specifically regarding deployment progress and the timeline for revenue ramp-up. He also asked about the recent decline in Wisp's EBITDA margins, its causes, and the potential impact on the timing of a sale.

    Answer

    Chairman and CEO Hamed Shahbazi reported that the OceanMD deployment in BC is on track, but they are awaiting next steps from the province, which is undergoing a broader strategic review. Regarding Wisp, Shahbazi explained that the lower Q1 EBITDA is a predictable seasonal pattern resulting from a strategic increase in advertising spend early in the year. He expressed confidence that margins will improve through 2025 and does not expect this to delay the divestiture process.

    Ask Fintool Equity Research AI

    David Kwan's questions to WELL Health Technologies Corp (WHTCF) leadership • Q3 2024

    Question

    David Kwan asked for the mix of acquisitions versus absorptions in the longer-term pipeline of over 30 clinics. He also inquired about M&A opportunities and current valuation multiples in the diagnostics and specialty health business.

    Answer

    Chairman and CEO Hamed Shahbazi responded that the future clinic pipeline is more balanced between absorptions and traditional acquisitions, with a focus on adding strong operators and maximizing unlevered ROIC, not just acquiring "cheap-off" clinics. Regarding diagnostics, he noted that valuation multiples have moderated, creating a great opportunity to acquire high-quality radiology and cardiology assets, and signaled that WELL expects to be active in this area in the coming quarters.

    Ask Fintool Equity Research AI